Navigation Links
CareFusion Provides Update on Previously Announced Ventilator Recall
Date:12/22/2011

SAN DIEGO, Dec. 22, 2011 /PRNewswire/ -- CareFusion issued the following update regarding the voluntary recall of AVEA® ventilators it initiated in September. The FDA has now classified this action as a Class I recall.

There is no change to the remediation plans previously announced by the company and CareFusion is actively remediating the hardware on affected units. The recall affects AVEA ventilators and spare parts manufactured between March 1, 2009 and June 30, 2011 and therefore has no affect on the company's current production or shipping processes.

In September 2011, the company sent an urgent Medical Device Recall Notification to customers stating the identified potential risks associated with AVEA ventilators. Affected units may produce an extended high Ppeak alarm, which initiates audio and visual alarms, followed by the opening of the safety valve. No breaths are delivered during this alarm condition, instead the safety and exhalation valves open allowing the patient to breathe from room air and activating the safety valve alarm. A Class I recall is defined as a reasonable probability of serious adverse health consequences or death associated with use of the defective units.

The company had determined the root cause for the issue and is committed to updating each device in a timely manner with minimal disruption to customers. More information about the recall is available at: http://www.carefusion.com/customer-support/alerts-notices/medical-device-recall-avea-ventilator.aspx.

The company recorded a reserve in its 2012 fiscal first quarter related to this recall and continues to believe the amount to be sufficient to fulfill its remediation obligations.

Instructions to customers
Customer inquiries related to this action should be addressed to CareFusion Technical Support at 800-554
'/>"/>

SOURCE CareFusion
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. CareFusion Showcases Medication Management Technologies at American Society for Health-System Pharmacists Conference
2. CareFusion Launches Wireless Diagnostic and Monitoring Neurological Device
3. CareFusion Announces New Ventilation Solution to Help Hospitals Provide Improved Patient Care and Reduce Costs
4. CareFusion Initiates Class I Recall of EnVe Ventilators
5. CareFusion Launches New Emergency Transport Ventilator
6. B. Braun Medical Sues CareFusion for Patent Infringement
7. CareFusion Reports Fourth Quarter and Fiscal 2011 Results
8. CareFusion and ResMed Announce Distribution Agreement for U.S. Hospital Market
9. CareFusion Will Host an Earnings Conference Call on Aug. 8 to Discuss the Results for the Fourth Quarter and Fiscal 2011
10. CareFusion to Acquire Pharmacy Automation Innovator Rowa
11. CareFusion Reports Third Quarter Rise in Revenue, Earnings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... Research and Markets ( http://www.researchandmarkets.com/research/tjlw9k/immunoprotein ) ... Diagnostic Testing Market - Forecasts to 2019: Expected ... and is expected to be valued at USD ... http://photos.prnewswire.com/prnh/20130307/600769 ... segmented according to immunoprotein types which include immunoglobulins, ...
(Date:7/11/2014)... July 11, 2014 ... Safety & Health Expo 2014 were a ... to London , plus ... exhibition.          (Logo: ... )      (Photo: ...
(Date:7/10/2014)... July 11, 2014  Major advances in radiation ... are being highlighted in a three-day Oncology Summit ... from 10-12 July, 2014.  Renowned national and international cancer experts ... practices and exchange knowledge on modern technologies making ... efficient. The Summit will address ...
Breaking Medicine Technology:Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5
... Aug. 17, 2011 Reportlinker.com announces that ... in its catalogue: Levosimendan ... http://www.reportlinker.com/p0483048/Levosimendan---Comprehensive-patent-search.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology Eliminate unnecessary ... patent information. Pipeline Developer is ...
... 16, 2011 Savient Pharmaceuticals, Inc. (NASDAQ: ... KRYSTEXXA® (pegloticase) Phase III clinical studies in patients with ... The Journal of the American Medical Association ( ... resulted in significant and sustained reductions in uric acid ...
Cached Medicine Technology:Levosimendan - Comprehensive Patent Search 2Levosimendan - Comprehensive Patent Search 3Levosimendan - Comprehensive Patent Search 4Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 2Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 3Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 4Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 5Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 6Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 7Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 8
(Date:7/11/2014)... Williamsburg, VA (PRWEB) July 11, 2014 Riverside ... Continuing Care (CBCC) in Virginia in late 2012 and ... – ChooseHome – to residents throughout the Williamsburg and Newport ... CBCC programs provide services and benefits to independent older adults ... have access to a safety net of continuing care services ...
(Date:7/11/2014)... TX (PRWEB) July 11, 2014 Last ... their staff. Jim Siddons joins the agency as a ... graduated in 1994 with a Bachelor’s Degree in Business ... of industry experience and will manage everything from performance ... for trucking to the specialized needs for those in ...
(Date:7/11/2014)... Europe is one of the largest consumers ... irrigated land area. The agricultural sector is a significant ... 30.0% of the total water use. The scale and ... region, but far from negligible in most northern ones. ... 60.0% of the water use in most countries, while ...
(Date:7/11/2014)... The “Proteomics Market by Technology (Protein Microarray, ... Resonance, X-ray Crystallography) - Instruments, Reagents & Services ... the major market drivers, restraints, and opportunities in ... the World (RoW). , The proteomics market has ... mainly due to the increasing need of proteomic ...
(Date:7/11/2014)... Pigments are insoluble colorants, which usually ... namely protective coating, opacity, and coloring. These are water ... color to substances such as paper, paints, plastics, and ... upon application impart color to the substance. Some examples ... and hematite. , The coloring action of pigments is ...
Breaking Medicine News(10 mins):Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 2Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 3Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 4Health News:Europe Micro Irrigation System Market Driven by Growing Environmental Concerns and Decreasing Water Availability - New Report by MicroMarket Monitor 2Health News:Europe Micro Irrigation System Market Driven by Growing Environmental Concerns and Decreasing Water Availability - New Report by MicroMarket Monitor 3Health News:Proteomics Market Worth $20,696.4 Million by 2018 - New Report By MarketsandMarkets 2Health News:Proteomics Market Worth $20,696.4 Million by 2018 - New Report By MarketsandMarkets 3Health News:Proteomics Market Worth $20,696.4 Million by 2018 - New Report By MarketsandMarkets 4Health News:Americas Pigments Market Worth 1,099 Thousand MT by 2018 - New Report by MicroMarket Monitor 2Health News:Americas Pigments Market Worth 1,099 Thousand MT by 2018 - New Report by MicroMarket Monitor 3
... HARRISBURG, Pa., Jan. 3 Consumers who,purchased or ... from,the Schumacher,s Inn in Austin, Potter County, should ... Botulism contamination, Health Secretary Dr. Calvin B.,Johnson said ... the restaurant should,immediately contact the Pennsylvania Department of ...
... (OTC,Bulletin Board: RXEI), a developer, manufacturer, and marketer ... a registration,statement covering the resale of 53,747,555 shares ... and Exchange Commission on January,2, 2008., This ... does not,represent a solicitation or offer to buy ...
... mind can affect the body,s health, researchers say , , THURSDAY, ... say they have prescribed a placebo to a patient during ... A majority of doctors in the study also said they ... accept a mind-body relationship that can affect health, the ...
... faster cancer growth and earlier death, agency says ... studies offer further evidence of the health risks posed ... U.S. officials announced Thursday. , The studies showed that ... the drugs as treatment for chemotherapy-induced anemia died sooner ...
... treated for hypothyroidism aren,t likely to drop pounds with ... the Journal of Pediatrics. The study is the first ... loss in pediatric patients., Parents of overweight children ... request thyroid tests, but, unfortunately, screening for hypothyroidism is ...
... with radiation, finding no raised risk to heart , , ... that a common but controversial treatment for prostate cancer ... of heart problems, as some specialists had feared. ... a combination of testosterone-lowering drugs and radiation therapy appeared ...
Cached Medicine News:Health News:Health Department Warns Consumers of Home-Canned Soup Linked to Potter County Restaurant 2Health News:RxElite Registration Statement Declared Effective by Securities and Exchange Commission 2Health News:Almost Half of Doctors Have Prescribed Placebos 2Health News:FDA Reports New Risks Posed by Anemia Drugs 2Health News:FDA Reports New Risks Posed by Anemia Drugs 3Health News:Thyroid treatment no 'quick fix' for weight loss in children 2Health News:Combo Therapy Cuts Prostate Cancer Death Rates 2Health News:Combo Therapy Cuts Prostate Cancer Death Rates 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: